Allergy Therapeutics Share Discussion Threads

[coinbase] 15/12/2023 20:41

Jimmyloser, the Alternative Investment Market is dead. There’s hardly any liquidity and there’s certainly no appetite for sensible science. There’s some money to be made in the commodity space, but not much. This has the potential to be a multibillion-pound business, but not while it’s listed here.

[jimmyloser] 15/12/2023 17:20

My thinking on the nail. I suspect that due to the lack of either understanding or credibility or both that peeps have not grasped the sheer meaning of the results announced this week.This RNS today is hogwash and no more than another snake to slide down.Patience.impo of course.

[coinbase] 15/12/2023 17:13

Our two largest shareholders must be rubbing their hands together. If I was them I would take this private early next year and relist on the NASDAQ in 2025. I couldn’t careless about BDO or their inability to audit the company in a timely manner. What matters to me is the science!

[jimmyloser] 15/12/2023 16:44

Holding shares in AGY is akin to playing snakes and ladders!impo.

[amishp67] 15/12/2023 15:41

This share price should be 0.01 p

[vergeltung] 15/12/2023 13:25

Expressions involving drunken parties and breweries come to mind.
This board is utterly incompetent and seems unable to do the most fundamental of things. I suppose they were taken by surprise by the need to file accounts - oh, wait, it LITERALLY HAPPENS EVERY YEAR and they have 6 months to prepare. Somehow every other company manages this - so boring - every 12 months.
Meanwhile the CEO exercises a load of options despite what must count as one of the worst performances for shareholders ever seen on AIM (against some stiff competition).
It's a shameless crew 'running' a great little company.

[amishp67] 15/12/2023 12:58

Suspension on 2nd Jan 2024...shambles once again

[coinbase] 07/12/2023 19:05

Solid after-hours print. The market makers are having a field day at our expense.

[beccasan] 06/12/2023 14:22

Your approach is much better now. I have lost a lot of money and over many years I believe I bring value to the chat by preventing others from losing by following senseless illusions and suggestions. Then I don't care about the rest. If, as I think I understand, what I say is misunderstood, I live on something else and with something else. Latest post by beccasan, good luck to you all. Merry Christmas, to Jimmy too.

[vergeltung] 06/12/2023 14:07

beccasan, you say "you should go into the merits of the issues. I just do this. I'll get into the matter" - fine, you hold strongly negative views, but my question remains: why are you doing this and spending your precious time sharing them with us?

[beccasan] 06/12/2023 13:51

You believe me to be very powerful and make serious and biased statements. Very serious. Instead of making inferences you should go into the merits of the issues. I just do this. I'll get into the matter. Then, again in accordance with what you said, no one has ever bought this company, ever, because there is nothing to buy. And I believe that will remain the case until its business model changes. About you, I have no opinion.

[vergeltung] 06/12/2023 13:33

I wonder why beccasan is posting on this thread; they cannot be a shareholder with the opinions they write - so is beccasan a disinterested third party giving us the benefit of their negative views out of pure altruism? Or do they work for a competitor, maybe even one interested in acquiring AGY at a depressed price?

[jimmyloser] 06/12/2023 12:59

beccasan,
As it is the season of goodwill (yes, there is such a thing) I have voted your post 'up' and I hope that is snows where you are and Santa is kind to you.

🎅

[beccasan] 06/12/2023 12:27

I find all this surreal. talking about % growth when the shares are worth 1c is absurd. Rejoicing over the preliminary results of a study that hasn't even been published, we don't even know if anyone will ever publish it, if an authority will ever judge it sufficient, if the product will ever be registered and, finally, if this product will ever produce sales in 5 years is absurd and stupid. We are talking about a company that would have failed and gone bankrupt if not kept artificially alive through constant and significant external subsidization. We are talking about a remote future when we don't even know how the first half of the turnover will end. And I believe it will be a further disaster.

[jpuff] 05/12/2023 14:50

Fingers crossed

[red army] 04/12/2023 19:41

I still think a long way to go given the IP in place.

[jimmyloser] 04/12/2023 08:21

Jimmy sticks his neck out.............

"These shares will become one of the most sought after on AIM this side of Christmas"

dyor/impo.

[jimmyloser] 02/12/2023 10:27

Amishp67


Please elaborate if you can - thanks

[amishp67] 02/12/2023 10:11

Yes but what's the point when someone else will benefit..

[jimmyloser] 01/12/2023 14:36

Results mid December......................

The adaptive G306 study design, endorsed by regulators, allowed an interim analysis to determine whether a 2nd cohort would be required. The trial met its primary endpoint demonstrating statistically significant superiority of Grass MATA MPL compared to placebo (p <=0.0024, one-sided) in the CSMS during the peak pollen season, and ..........................(Drum Roll)...........the study was stopped for success.

[jimmyloser] 14/11/2023 13:37

Whilst this mornings RNS was appreciated, it was no great surprise to me.

A 16% price increase is very welcome and the breakthrough by AGY a company currently based in Britain is nice to see.

Both commercially and medically this is much needed news and I look forward to a continued flow of further upbeat news releases in the weeks ahead.

As all know, I have remained optimistic, today was the first step in the right direction.

CONGRATULATIONS TO ALL AT AGY ON THIS OUTSTANDING ACHIEVEMENT

Potentially, what's next for us?

Positive trial results imminently? - Achieved, thanks.✔
Consolidation?
Progress on peanuts.?
Successful fund raising?
Expansion of markets?

“This time next year, who knows”😊;😊
Impo/dyor

[red army] 14/11/2023 11:22

That will be a great pity as we all get shafted. Its not as though the companys doesnt have a great future ahead

[coinbase] 14/11/2023 09:49

Red Army, if the price doesn’t move up significantly this side of Christmas then I can see our two largest shareholders taking it private for somewhere in the region of 5 GBX.

[tomboyb] 14/11/2023 09:39

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")



G306 pivotal Phase III trial to evaluate efficacy and safety of Grass MATA MPL meets primary endpoint



- Study demonstrated a highly statistically significant reduction in Combined Symptom & Medication Score (CSMS) (p≤0.0024) achieved in active treatment group compared to placebo



- Analysis of primary outcome and secondary endpoints including quality of life and biomarkers to be announced once full analysis of the data has been completed



14 November 2023 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, today announces interim top line results from its pivotal G306 Phase III trial of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.



The adaptive G306 study design, endorsed by regulators, allowed an interim analysis to determine whether a 2nd cohort would be required. The trial met its primary endpoint demonstrating statistically significant superiority of Grass MATA MPL compared to placebo (p ≤0.0024, one-sided) in the CSMS during the peak pollen season, and the study was stopped for success. Top line analysis is expected to be available in mid-December. This will include treatment effect data and secondary endpoint analysis.



The G306 trial was a multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to evaluate the efficacy of Grass MATA MPL 27600 SU in subjects with grass pollen induced seasonal allergic rhinitis and/or rhinoconjunctivitis based on symptoms and medications. The trial was conducted in the US and Europe at 89 sites.



Manuel Llobet, CEO at Allergy Therapeutics, stated: "The completion of the G306 study is an important milestone in our efforts to register this innovative treatment for the benefit of the millions of patients affected by grass allergies. I would like to thank our trial investigators, the team at Allergy Therapeutics and, most importantly, the patients, for their contributions. This result builds upon the statistical significance also seen in the earlier G3091 field study and, subject to full top line analysis, we look forward to commencing discussions with relevant regulatory authorities to continue our journey to bring this important product to market."